239 related articles for article (PubMed ID: 38203310)
21. Prognostic value of abnormally expressed lncRNAs in ovarian carcinoma: a systematic review and meta-analysis.
Luo P; Liu XF; Wang YC; Li ND; Liao SJ; Yu MX; Liang CZ; Tu JC
Oncotarget; 2017 Apr; 8(14):23927-23936. PubMed ID: 28118613
[TBL] [Abstract][Full Text] [Related]
22. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
23. Long non‑coding RNA NEAT1 promotes ovarian cancer cell invasion and migration by interacting with miR‑1321 and regulating tight junction protein 3 expression.
Luo M; Zhang L; Yang H; Luo K; Qing C
Mol Med Rep; 2020 Oct; 22(4):3429-3439. PubMed ID: 32945443
[TBL] [Abstract][Full Text] [Related]
24. LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms.
Braga EA; Fridman MV; Moscovtsev AA; Filippova EA; Dmitriev AA; Kushlinskii NE
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238475
[TBL] [Abstract][Full Text] [Related]
25. The Role of EMT-Related lncRNAs in Ovarian Cancer.
Lampropoulou DI; Papadimitriou M; Papadimitriou C; Filippou D; Kourlaba G; Aravantinos G; Gazouli M
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373222
[TBL] [Abstract][Full Text] [Related]
26. Profile and validation of dysregulated long non‑coding RNAs and mRNAs in ovarian cancer.
Lu YM; Wang Y; Liu SQ; Zhou MY; Guo YR
Oncol Rep; 2018 Nov; 40(5):2964-2976. PubMed ID: 30132558
[TBL] [Abstract][Full Text] [Related]
27. Risk of venous thromboembolism and bleeding after major surgery for ovarian cancer: standard in-hospital versus extended duration of thromboprophylaxis.
Wiegers HMG; Schaafsma M; Guman NAM; Zelisse HS; Mulder FI; Middeldorp S; van Es N; Mom CH
J Thromb Haemost; 2023 Feb; 21(2):294-302. PubMed ID: 36700503
[TBL] [Abstract][Full Text] [Related]
28. Ectopic expressed long non-coding RNA H19 contributes to malignant cell behavior of ovarian cancer.
Zhu Z; Song L; He J; Sun Y; Liu X; Zou X
Int J Clin Exp Pathol; 2015; 8(9):10082-91. PubMed ID: 26617715
[TBL] [Abstract][Full Text] [Related]
29. Identification of pathological grade and prognosis-associated lncRNA for ovarian cancer.
Chen Y; Bi F; An Y; Yang Q
J Cell Biochem; 2019 Sep; 120(9):14444-14454. PubMed ID: 31034644
[TBL] [Abstract][Full Text] [Related]
30. Upregulation of long non‑coding RNA CCEPR is associated with poor prognosis and contributes to the progression of ovarian cancer through regulating the Wnt/β‑catenin signaling pathway.
Chen Z; Zhu Y; Fan X; Liu Y; Feng Q
Mol Med Rep; 2020 Apr; 21(4):1950-1958. PubMed ID: 32319633
[TBL] [Abstract][Full Text] [Related]
31. Long non-coding RNA EPB41L4A-AS2 suppresses progression of ovarian cancer by sequestering microRNA-103a to upregulate transcription factor RUNX1T1.
Sun T; Yang P; Gao Y
Exp Physiol; 2020 Jan; 105(1):75-87. PubMed ID: 31645082
[TBL] [Abstract][Full Text] [Related]
32. Oct4 transcriptionally regulates the expression of long non-coding RNAs NEAT1 and MALAT1 to promote lung cancer progression.
Jen J; Tang YA; Lu YH; Lin CC; Lai WW; Wang YC
Mol Cancer; 2017 Jun; 16(1):104. PubMed ID: 28615056
[TBL] [Abstract][Full Text] [Related]
33. The timing of venous thromboembolism in ovarian cancer patients: A nationwide Danish cohort study.
Strøm Kahr H; Christiansen OB; Juul Riddersholm S; Gade IL; Torp-Pedersen C; Knudsen A; Thorlacius-Ussing O
J Thromb Haemost; 2021 Apr; 19(4):992-1000. PubMed ID: 33420762
[TBL] [Abstract][Full Text] [Related]
34. Identification of oncogenic long noncoding RNAs CASC9 and LINC00152 in oral carcinoma through genome-wide comprehensive analysis.
Chen M; Xu X; Ma H
Anticancer Drugs; 2019 Apr; 30(4):356-362. PubMed ID: 30543527
[TBL] [Abstract][Full Text] [Related]
35. High incidence of silent venous thromboembolism before treatment in ovarian cancer.
Satoh T; Oki A; Uno K; Sakurai M; Ochi H; Okada S; Minami R; Matsumoto K; Tanaka YO; Tsunoda H; Homma S; Yoshikawa H
Br J Cancer; 2007 Oct; 97(8):1053-7. PubMed ID: 17895896
[TBL] [Abstract][Full Text] [Related]
36. LncRNA FGD5-AS1 promotes the malignant phenotypes of ovarian cancer cells via targeting miR-142-5p.
Aichen Z; Kun W; Xiaochun S; Lingling T
Apoptosis; 2021 Jun; 26(5-6):348-360. PubMed ID: 33974163
[TBL] [Abstract][Full Text] [Related]
37. Long non-coding RNA CTSLP8 mediates ovarian cancer progression and chemotherapy resistance by modulating cellular glycolysis and regulating c-Myc expression through PKM2.
Li X; Zhang Y; Wang X; Lin F; Cheng X; Wang Z; Wang X
Cell Biol Toxicol; 2022 Dec; 38(6):1027-1045. PubMed ID: 34510316
[TBL] [Abstract][Full Text] [Related]
38. Long non-coding RNA FAM83H-AS1 acts as a potential oncogenic driver in human ovarian cancer.
Yuan X; Huang Y; Guo M; Hu X; Li P
J Ovarian Res; 2021 Jan; 14(1):6. PubMed ID: 33413565
[TBL] [Abstract][Full Text] [Related]
39. Incidence of venous thromboembolism after standard treatment in patients with epithelial ovarian cancer in Korea.
Shin W; Lee S; Lim MC; Jung J; Kim HJ; Cho H
Cancer Med; 2021 Mar; 10(6):2045-2053. PubMed ID: 33638309
[TBL] [Abstract][Full Text] [Related]
40. MicroRNAs as prognostic biomarkers for (cancer-associated) venous thromboembolism.
Anijs RJS; Nguyen YN; Cannegieter SC; Versteeg HH; Buijs JT
J Thromb Haemost; 2023 Jan; 21(1):7-17. PubMed ID: 36695398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
